Skin Cancer
Rous Sarcoma Virus (RSV) and Cancer
The JAK-STAT Signaling Pathway
Treatment Resistant Cancers
Cancer Therapies
Abnormal Proliferation
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 28, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Patients treated with Ruxolitinib for myelofibrosis experienced a higher incidence of numerous, aggressive skin cancers. Further research into JAK inhibitors and skin cancer risk is warranted.
Area of Science:
Background: